AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22250853 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior involvement with alcohol or drugs
Number of subjects: 192
Study 22250853 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 192
Study 22250853 — intervention group
Group type: EXPERIMENTAL
Intervention: More comorbid disorders
Number of subjects: 192
Study 22250853 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent MDD and AUD
Number of subjects: 192
Study 19489492 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuzhen therapy
Number of subjects: 60
Study 19489492 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture therapy
Number of subjects: 60
Study 17360077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 19
Study 17360077 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS)
Number of subjects: 19
Study 15006466 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 45
Study 15006466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15006466 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg modafinil
Number of subjects: 45
Study 11769996 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone tablets
Number of subjects: 41
Study 11769996 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen inhalation
Number of subjects: 41
Study 11769996 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 41
Study 11769996 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air inhalation
Number of subjects: 41
Study 10065224 — intervention group
Group type: EXPERIMENTAL
Intervention: Child RAND (asthma group)
Number of subjects: 348
Study 10065224 — intervention group
Group type: COMPARATOR
Intervention: Child RAND (control group)
Number of subjects: 348
Study 10065224 — intervention group
Group type: EXPERIMENTAL
Intervention: Child RAND (children with health complaints)
Number of subjects: 348
Study 10065224 — intervention group
Group type: COMPARATOR
Intervention: Child RAND (children without health complaints)
Number of subjects: 348
Study 10065224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to change of Child RAND
Number of subjects: 348
Study 10065224 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability and validity measures of Child RAND
Number of subjects: 348
Study 8021796 — intervention group
Group type: EXPERIMENTAL
Intervention: Single unit of packed red blood cells until expiration (35 days)
Number of subjects: 0
Study 8021796 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2503490 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, orally)
Number of subjects: 22
Study 2503490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 790293 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 47
Study 790293 — intervention group
Group type: COMPARATOR
Intervention: imipramine
Number of subjects: 47
Study 31279405 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 2764
Study 31279405 — intervention group
Group type: COMPARATOR
Intervention: Biolimus-eluting stents (BES)
Number of subjects: 2764
Study 28120497 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (with optional uptitration to 300 mg)
Number of subjects: 5812
Study 28120497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5812
Study 29911577 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental knee pain (hypertonic saline injection)
Number of subjects: 10
Study 29911577 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic saline injection)
Number of subjects: 10
Study 23144045 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced cycling
Number of subjects: 0
Study 23144045 — intervention group
Group type: COMPARATOR
Intervention: Voluntary cycling
Number of subjects: 0
Study 21227540 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous metoclopramide
Number of subjects: 356
Study 21227540 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous metoclopramide
Number of subjects: 356
Study 21227540 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intravenous metoclopramide
Number of subjects: 356
Study 21227540 — intervention group
Group type: COMPARATOR
Intervention: Overall study population
Number of subjects: 356
Study 18306984 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line treatment with pantoprazole (40 mg twice daily), amoxicillin (1000 mg twice daily), and clarithromycin (500 mg) for 7 days
Number of subjects: 134
Study 18306984 — intervention group
Group type: COMPARATOR
Intervention: Second-line treatment with ranitidine bismuth citrate (400 mg twice daily), metronidazole (250 mg twice daily), and clarithromycin (500 mg) for 7 days
Number of subjects: 134
Study 18306984 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line quadruple therapies with pantoprazole + amoxicillin and tetracycline (500 mg four times daily) and either nitrofurantoin (100 mg three times daily) or bismuth subsalicylate (120 mg four times daily)
Number of subjects: 134
Study 17175821 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate, meperidine, and hydroxyzine (regimen A)
Number of subjects: 16
Study 17175821 — intervention group
Group type: COMPARATOR
Intervention: Midazolam, meperidine, and hydroxyzine (regimen B)
Number of subjects: 16
Study 12676059 — intervention group
Group type: EXPERIMENTAL
Intervention: First-order (luminance-defined) motion stimuli
Number of subjects: 0
Study 12676059 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-order (texture-defined) motion stimuli
Number of subjects: 0
Study 12676059 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 11058672 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir (10 mg twice a day for 5 days for index cases, 10 mg once a day for 10 days for family members)
Number of subjects: 1158
Study 11058672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1158
Study 11058672 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir
Number of subjects: 1158
Study 8826739 — intervention group
Group type: EXPERIMENTAL
Intervention: VHF + RT
Number of subjects: 73
Study 8826739 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 73
Study 1411408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/d)
Number of subjects: 52
Study 1411408 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/d)
Number of subjects: 52
Study 3914703 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/qd
Number of subjects: 49
Study 3914703 — intervention group
Group type: COMPARATOR
Intervention: Sulindac 200 mg twice a day
Number of subjects: 49
Study 31251548 — intervention group
Group type: EXPERIMENTAL
Intervention: Kamedis Eczema Therapy Cream (tested product)
Number of subjects: 108
Study 31251548 — intervention group
Group type: EXPERIMENTAL
Intervention: Leading OTC brand (comparator)
Number of subjects: 108
Study 31251548 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 108
Study 28918674 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Fruitflow®
Number of subjects: 12
Study 26177151 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability training
Number of subjects: 20
Study 26177151 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard warm-up)
Number of subjects: 20
Study 25284142 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral fundoplication (TF)
Number of subjects: 63
Study 25284142 — intervention group
Group type: COMPARATOR
Intervention: High-dose proton-pump inhibitors (HD PPIs)
Number of subjects: 63
Study 22409309 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (12.5 mg)
Number of subjects: 23
Study 22409309 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 23
Study 22409309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 20174834 — intervention group
Group type: EXPERIMENTAL
Intervention: landiolol 0.1 mg/kg
Number of subjects: 180
Study 20174834 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine 0.02 mg/kg
Number of subjects: 180
Study 20174834 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 180
Study 18472103 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg
Number of subjects: 251
Study 18472103 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 251
Study 16018750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-B complex supplementation (50 mg of thiamine HCl, riboflavin, niacinamide, d-calcium pantothenate, pyridoxine HCl; 50 microg each of d-biotin and cyanocobalamin; and 400 mcg of folate) for 30 days after AFS
Number of subjects: 30
Study 16018750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-B complex supplementation
Number of subjects: 30
Study 16018750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16018750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-B complex supplementation and placebo
Number of subjects: 30
Study 12454519 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (Group B)
Number of subjects: 128
Study 12454519 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant locoregional chemoimmunotherapy (Group C)
Number of subjects: 128
Study 12454519 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection alone (Group A)
Number of subjects: 128
Study 10609206 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased atmospheric pressure (hyperbaric chamber for 1 hour)
Number of subjects: 8
Study 10609206 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and sex matched eyes without RK)
Number of subjects: 8
Study 7499110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulofenur 640 mg/M2
Number of subjects: 13
Study 7499110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulofenur 800 mg/M2
Number of subjects: 13
Study 7499110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulofenur 960 mg/M2
Number of subjects: 13
Study 7499110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulofenur (all dosages)
Number of subjects: 13
Study 1959341 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) 6 g/day for 3 months
Number of subjects: 36
Study 1959341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6765542 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin combination with 20% regular and 80% NPH
Number of subjects: 10
Study 6765542 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin combination with 30% regular and 70% NPH
Number of subjects: 10
Study 6765542 — intervention group
Group type: COMPARATOR
Intervention: PPI 30/70 combination
Number of subjects: 10
Study 31600414 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered mindfulness-based cognitive therapy (iMBCT)
Number of subjects: 150
Study 31600414 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU) wait-list
Number of subjects: 150
Study 31119881 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-weighing (DSW) with visual graphical feedback (GF)
Number of subjects: 111
Study 31119881 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study 28635352 — intervention group
Group type: EXPERIMENTAL
Intervention: OB/Mobius® retractor
Number of subjects: 154
Study 28635352 — intervention group
Group type: COMPARATOR
Intervention: Conventional retraction instruments
Number of subjects: 154
Study 25919921 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartLoss
Number of subjects: 40
Study 25919921 — intervention group
Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 40
Study 24086658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (10,000 lux)
Number of subjects: 0
Study 24086658 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (< 500 lux)
Number of subjects: 0
Study 21843968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrified sibling oocytes
Number of subjects: 31
Study 21843968 — intervention group
Group type: COMPARATOR
Intervention: Fresh sibling oocytes
Number of subjects: 31
Study 20108207 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg/day of folic acid (verum)
Number of subjects: 46
Study 20108207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 16395260 — intervention group
Group type: EXPERIMENTAL
Intervention: FK352 (50 mg, intravenous)
Number of subjects: 30
Study 16395260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16395260 — intervention group
Group type: EXPERIMENTAL
Intervention: FK352
Number of subjects: 30
Study 15085364 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP measurements
Number of subjects: 100
Study 15085364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea score
Number of subjects: 100
Study 10935580 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anesthesia
Number of subjects: 23
Study 10935580 — intervention group
Group type: COMPARATOR
Intervention: Normotensive anesthesia
Number of subjects: 23
Study 9008601 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (rIFN gamma) 50 micrograms subcutaneously over 24 weeks
Number of subjects: 197
Study 9008601 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections at the same time frequency
Number of subjects: 197
Study 8497357 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard skin preparation plus normal saline irrigation
Number of subjects: 100
Study 8497357 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preparation plus antibiotic irrigation
Number of subjects: 100
Study 8497357 — intervention group
Group type: EXPERIMENTAL
Intervention: Special preparation plus normal saline irrigation
Number of subjects: 100
Study 8497357 — intervention group
Group type: EXPERIMENTAL
Intervention: Special preparation plus antibiotic irrigation
Number of subjects: 100
Study 8497357 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine alone
Number of subjects: 100
Study 2887615 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 32
Study 2887615 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine or Ranitidine
Number of subjects: 32
Study 31571089 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion of fatty acids of the ω‐3 series
Number of subjects: 40
Study 31571089 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (0.15%)‐based tear substitute
Number of subjects: 40
Study 28922936 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 189
Study 28922936 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 189
Study 28922936 — intervention group
Group type: COMPARATOR
Intervention: Neutral thinking
Number of subjects: 189
Study 28660739 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 SQ HDM sublingual immunotherapy tablet
Number of subjects: 395
Study 25694217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day) for 6 weeks
Number of subjects: 16
Study 25694217 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 16
Study 23775581 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (mean dose 9.8 ± 3.6 mg/kg/day)
Number of subjects: 130
Study 23775581 — intervention group
Group type: COMPARATOR
Intervention: Deferasirox (mean dose in extension 13.7 ± 4.6 mg/kg/day)
Number of subjects: 130
Study 23775581 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 130
Study 21361981 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 2
Study 21361981 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 2
Study 21361981 — intervention group
Group type: COMPARATOR
Intervention: Consistency-driven responses
Number of subjects: 2
Study 19032121 — intervention group
Group type: EXPERIMENTAL
Intervention: FFNS 110 microg
Number of subjects: 240
Study 19032121 — intervention group
Group type: EXPERIMENTAL
Intervention: FFNS 220 microg
Number of subjects: 240
Study 19032121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 16575712 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Outpatient Physiotherapy (EAP)
Number of subjects: 1274
Study 16575712 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient Rehabilitation (AR)
Number of subjects: 1274
Study 16575712 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Training Therapy (MTT)
Number of subjects: 1274
Study 16575712 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1274
Study 15353533 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiluted APSV
Number of subjects: 340
Study 15353533 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:5 dilution APSV
Number of subjects: 340
Study 15353533 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10 dilution APSV
Number of subjects: 340
Study 15353533 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 340
Study 11851735 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (physiotherapy, casting, strengthening, and/or orthoses)
Number of subjects: 0
Study 11851735 — intervention group
Group type: EXPERIMENTAL
Intervention: Spasticity management (intramuscular injections of phenol, alcohol, and botulinum toxin type A)
Number of subjects: 0
Study 11851735 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopaedic approaches
Number of subjects: 0
Study 9517912 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg twice daily)
Number of subjects: 219
Study 9517912 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (50 mg twice daily)
Number of subjects: 219
Study 8044618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivalon sponge rectopexy
Number of subjects: 63
Study 8044618 — intervention group
Group type: COMPARATOR
Intervention: Sutured rectopexy
Number of subjects: 63
Study 3403888 — intervention group
Group type: EXPERIMENTAL
Intervention: Base-in prism lenses
Number of subjects: 48
Study 3403888 — intervention group
Group type: COMPARATOR
Intervention: Plano lenses
Number of subjects: 48
Study 30423810 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve
Number of subjects: 0
Study 28054312 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Galvanic Vestibular Stimulation (GVS) pre-exposure
Number of subjects: 0
Study 28054312 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive pre-exposure to placebo stimulation
Number of subjects: 0
Study 28054312 — intervention group
Group type: EXPERIMENTAL
Intervention: Open pre-exposure to placebo stimulation
Number of subjects: 0
Study 26271700 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsorin (main study group)
Number of subjects: 84
Study 26271700 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (control group)
Number of subjects: 84
Study 22713081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) gel and 304% fluoride toothpaste
Number of subjects: 199
Study 22713081 — intervention group
Group type: COMPARATOR
Intervention: Control group (twice daily toothbrushing with toothpaste only)
Number of subjects: 199
Study 21693007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 1200
Study 21693007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus acute stage acupuncture
Number of subjects: 1200
Study 21693007 — intervention group
Group type: COMPARATOR
Intervention: Placebo prednisolone plus acute stage acupuncture
Number of subjects: 1200
Study 21693007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus resting stage acupuncture
Number of subjects: 1200
Study 21693007 — intervention group
Group type: COMPARATOR
Intervention: Placebo prednisolone plus resting stage acupuncture
Number of subjects: 1200
Study 21693007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus acupuncture
Number of subjects: 1200
Study 18971385 — intervention group
Group type: EXPERIMENTAL
Intervention: FES plus conventional occupational and physiotherapy
Number of subjects: 21
Study 18971385 — intervention group
Group type: COMPARATOR
Intervention: Only conventional therapy (control group)
Number of subjects: 21
Study 18971385 — intervention group
Group type: EXPERIMENTAL
Intervention: Only FES therapy (chronic group)
Number of subjects: 21
Study 16776696 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia
Number of subjects: 16
Study 16776696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Number of subjects: 16
Study 16776696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12588577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 12588577 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ 12.5 mg
Number of subjects: 320
Study 12588577 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ 25 mg
Number of subjects: 320
Study 11147378 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgical tracheostomy
Number of subjects: 30
Study 11147378 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy
Number of subjects: 30
Study 11147378 — intervention group
Group type: EXPERIMENTAL
Intervention: Translaryngeal tracheostomy
Number of subjects: 30
Study 11147378 — intervention group
Group type: COMPARATOR
Intervention: Surgical tracheostomy
Number of subjects: 30
Study 11147378 — intervention group
Group type: EXPERIMENTAL
Intervention: All three groups
Number of subjects: 30
Study 11147378 — intervention group
Group type: EXPERIMENTAL
Intervention: All three techniques
Number of subjects: 30
Study 9496386 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin monotherapy every two weeks (110 mg/m2) with filgrastim (5 micrograms/kg/daily) prophylactically on days 2‐12 of each cycle
Number of subjects: 167
Study 9496386 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin monotherapy every four weeks (110 mg/m2) with filgrastim (5 micrograms/kg/daily) prophylactically on days 2‐12 of each cycle
Number of subjects: 167